Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings United Therapeutics Corporation: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: United Therapeutics Corporation
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Rating Financials

United Therapeutics Corporation SectorUnited States
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA-
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth-
Long Term balance sheet growth-
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

United Therapeutics Corporation SectorUnited States
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

United Therapeutics Corporation SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

United Therapeutics Corporation SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

United Therapeutics Corporation SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
21.07B
A
905B
A
487B
BBB
400B
AA
330B
AA
281B
A
255B
AAA
248B
A
214B
A
178B
A
Average 331.76B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Ratings United Therapeutics Corporation